Cargando…

Autophagy activity is associated with membranous sodium iodide symporter expression and clinical response to radioiodine therapy in non-medullary thyroid cancer

Although non-medullary thyroid cancer (NMTC) generally has a good prognosis, 30–40% of patients with distant metastases develop resistance to radioactive iodine (RAI) therapy due to tumor dedifferentiation. For these patients, treatment options are limited and prognosis is poor. In the present study...

Descripción completa

Detalles Bibliográficos
Autores principales: Plantinga, Theo S., Tesselaar, Marika H., Morreau, Hans, Corssmit, Eleonora P. M., Willemsen, Brigith K., Kusters, Benno, van Engen-van Grunsven, A. C. H., Smit, Johannes W. A., Netea-Maier, Romana T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4990989/
https://www.ncbi.nlm.nih.gov/pubmed/27105307
http://dx.doi.org/10.1080/15548627.2016.1174802
_version_ 1782448777395699712
author Plantinga, Theo S.
Tesselaar, Marika H.
Morreau, Hans
Corssmit, Eleonora P. M.
Willemsen, Brigith K.
Kusters, Benno
van Engen-van Grunsven, A. C. H.
Smit, Johannes W. A.
Netea-Maier, Romana T.
author_facet Plantinga, Theo S.
Tesselaar, Marika H.
Morreau, Hans
Corssmit, Eleonora P. M.
Willemsen, Brigith K.
Kusters, Benno
van Engen-van Grunsven, A. C. H.
Smit, Johannes W. A.
Netea-Maier, Romana T.
author_sort Plantinga, Theo S.
collection PubMed
description Although non-medullary thyroid cancer (NMTC) generally has a good prognosis, 30–40% of patients with distant metastases develop resistance to radioactive iodine (RAI) therapy due to tumor dedifferentiation. For these patients, treatment options are limited and prognosis is poor. In the present study, expression and activity of autophagy was assessed in large sets of normal, benign and malignant tissues and was correlated with pathology, SLC5A5/hNIS (solute carrier family 5 member 5) protein expression, and with clinical response to RAI ablation therapy in NMTC patients. Fluorescent immunostaining for the autophagy marker LC3 was performed on 100 benign and 80 malignant thyroid tissues. Semiquantitative scoring was generated for both diffuse LC3-I intensity and number of LC3-II-positive puncta and was correlated with SLC5A5 protein expression and clinical parameters. Degree of diffuse LC3-I intensity and number of LC3-II-positive puncta scoring were not discriminative for benign vs. malignant thyroid lesions. Interestingly, however, in NMTC patients significant associations were observed between diffuse LC3-I intensity and LC3-II-positive puncta scoring on the one hand and clinical response to RAI therapy on the other hand (odds ratio [OR] = 3.13, 95% confidence interval [CI] =1.91–5.12, P = 0.01; OR = 5.68, 95%CI = 3.02–10.05, P = 0.002, respectively). Mechanistically, the number of LC3-II-positive puncta correlated with membranous SLC5A5 expression (OR = 7.71, 95%CI = 4.15–11.75, P<0.001), number of RAI treatments required to reach remission (P = 0.014), cumulative RAI dose (P = 0.026) and with overall remission and recurrence rates (P = 0.031). In conclusion, autophagy activity strongly correlates with clinical response of NMTC patients to RAI therapy, potentially by its capacity to maintain tumor cell differentiation and to preserve functional iodide uptake.
format Online
Article
Text
id pubmed-4990989
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-49909892017-02-24 Autophagy activity is associated with membranous sodium iodide symporter expression and clinical response to radioiodine therapy in non-medullary thyroid cancer Plantinga, Theo S. Tesselaar, Marika H. Morreau, Hans Corssmit, Eleonora P. M. Willemsen, Brigith K. Kusters, Benno van Engen-van Grunsven, A. C. H. Smit, Johannes W. A. Netea-Maier, Romana T. Autophagy Translational Research Papers Although non-medullary thyroid cancer (NMTC) generally has a good prognosis, 30–40% of patients with distant metastases develop resistance to radioactive iodine (RAI) therapy due to tumor dedifferentiation. For these patients, treatment options are limited and prognosis is poor. In the present study, expression and activity of autophagy was assessed in large sets of normal, benign and malignant tissues and was correlated with pathology, SLC5A5/hNIS (solute carrier family 5 member 5) protein expression, and with clinical response to RAI ablation therapy in NMTC patients. Fluorescent immunostaining for the autophagy marker LC3 was performed on 100 benign and 80 malignant thyroid tissues. Semiquantitative scoring was generated for both diffuse LC3-I intensity and number of LC3-II-positive puncta and was correlated with SLC5A5 protein expression and clinical parameters. Degree of diffuse LC3-I intensity and number of LC3-II-positive puncta scoring were not discriminative for benign vs. malignant thyroid lesions. Interestingly, however, in NMTC patients significant associations were observed between diffuse LC3-I intensity and LC3-II-positive puncta scoring on the one hand and clinical response to RAI therapy on the other hand (odds ratio [OR] = 3.13, 95% confidence interval [CI] =1.91–5.12, P = 0.01; OR = 5.68, 95%CI = 3.02–10.05, P = 0.002, respectively). Mechanistically, the number of LC3-II-positive puncta correlated with membranous SLC5A5 expression (OR = 7.71, 95%CI = 4.15–11.75, P<0.001), number of RAI treatments required to reach remission (P = 0.014), cumulative RAI dose (P = 0.026) and with overall remission and recurrence rates (P = 0.031). In conclusion, autophagy activity strongly correlates with clinical response of NMTC patients to RAI therapy, potentially by its capacity to maintain tumor cell differentiation and to preserve functional iodide uptake. Taylor & Francis 2016-04-22 /pmc/articles/PMC4990989/ /pubmed/27105307 http://dx.doi.org/10.1080/15548627.2016.1174802 Text en © 2016 The Author(s). Published with license by Taylor & Francis http://creativecommons.org/licenses/by/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.
spellingShingle Translational Research Papers
Plantinga, Theo S.
Tesselaar, Marika H.
Morreau, Hans
Corssmit, Eleonora P. M.
Willemsen, Brigith K.
Kusters, Benno
van Engen-van Grunsven, A. C. H.
Smit, Johannes W. A.
Netea-Maier, Romana T.
Autophagy activity is associated with membranous sodium iodide symporter expression and clinical response to radioiodine therapy in non-medullary thyroid cancer
title Autophagy activity is associated with membranous sodium iodide symporter expression and clinical response to radioiodine therapy in non-medullary thyroid cancer
title_full Autophagy activity is associated with membranous sodium iodide symporter expression and clinical response to radioiodine therapy in non-medullary thyroid cancer
title_fullStr Autophagy activity is associated with membranous sodium iodide symporter expression and clinical response to radioiodine therapy in non-medullary thyroid cancer
title_full_unstemmed Autophagy activity is associated with membranous sodium iodide symporter expression and clinical response to radioiodine therapy in non-medullary thyroid cancer
title_short Autophagy activity is associated with membranous sodium iodide symporter expression and clinical response to radioiodine therapy in non-medullary thyroid cancer
title_sort autophagy activity is associated with membranous sodium iodide symporter expression and clinical response to radioiodine therapy in non-medullary thyroid cancer
topic Translational Research Papers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4990989/
https://www.ncbi.nlm.nih.gov/pubmed/27105307
http://dx.doi.org/10.1080/15548627.2016.1174802
work_keys_str_mv AT plantingatheos autophagyactivityisassociatedwithmembranoussodiumiodidesymporterexpressionandclinicalresponsetoradioiodinetherapyinnonmedullarythyroidcancer
AT tesselaarmarikah autophagyactivityisassociatedwithmembranoussodiumiodidesymporterexpressionandclinicalresponsetoradioiodinetherapyinnonmedullarythyroidcancer
AT morreauhans autophagyactivityisassociatedwithmembranoussodiumiodidesymporterexpressionandclinicalresponsetoradioiodinetherapyinnonmedullarythyroidcancer
AT corssmiteleonorapm autophagyactivityisassociatedwithmembranoussodiumiodidesymporterexpressionandclinicalresponsetoradioiodinetherapyinnonmedullarythyroidcancer
AT willemsenbrigithk autophagyactivityisassociatedwithmembranoussodiumiodidesymporterexpressionandclinicalresponsetoradioiodinetherapyinnonmedullarythyroidcancer
AT kustersbenno autophagyactivityisassociatedwithmembranoussodiumiodidesymporterexpressionandclinicalresponsetoradioiodinetherapyinnonmedullarythyroidcancer
AT vanengenvangrunsvenach autophagyactivityisassociatedwithmembranoussodiumiodidesymporterexpressionandclinicalresponsetoradioiodinetherapyinnonmedullarythyroidcancer
AT smitjohanneswa autophagyactivityisassociatedwithmembranoussodiumiodidesymporterexpressionandclinicalresponsetoradioiodinetherapyinnonmedullarythyroidcancer
AT neteamaierromanat autophagyactivityisassociatedwithmembranoussodiumiodidesymporterexpressionandclinicalresponsetoradioiodinetherapyinnonmedullarythyroidcancer